Local News

• Lilly announces completion of SGX acquisition  Eli Lilly and Company announced that it has completed the acquisition of SGX Pharmaceuticals, a San Diego-based biotechnology company focused on drug discovery and development in the area of oncology.
  Eli Lilly and Company August 20, 2008  
• California licenses 2 companies to offer gene services  Two closely watched companies that offer consumers information about their genes have received licenses that will allow them to continue to do business in California, a state official said.
  The New York Times August 19, 2008  Andrew Pollack
• Elanco announces acquisition of Posilac(R) dairy business  Elanco, a division of Eli Lilly and Company, announced that Lilly has signed an agreement to acquire the worldwide rights to the dairy cow supplement, Posilac(R) (sometribove), as well as the product's supporting operations, from Monsanto Company.
  Eli Lilly and Company August 20, 2008  
• Eli Lilly and Company to acquire Monsanto's POSILAC brand dairy product  Monsanto Company announced that it has entered into an agreement to sell its POSILAC(R) bovine somatotropin brand and related business to Eli Lilly and Company. Lilly's animal health division, Elanco, is the seventh largest animal health company on a global sales basis.
  Monsanto Company August 20, 2008  
• BSD Medical’s high-end cancer treatment system performs with excellence  BSD Medical announced that a report of two case studies has been published in the International Journal of Hyperthermia that demonstrate the ability of the BSD-2000/3D/MR to produce high quality thermal imaging of cancer treatments in progress, even when interfering frequencies are introduced.
  BSD Medical Corporation August 20, 2008  
• BMS and PDL BioPharma enter alliance to develop novel treatment for multiple myeloma  Bristol-Myers Squibb Company and PDL BioPharma announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzumab, previously known as HuLuc63, currently in Phase I development for multiple myeloma.
  Bristol-Myers Squibb Company August 19, 2008  
• Patient side point-of-care testing enables quicker treatment decisions  Patient side point-of-care testing - where diagnostic testing is conducted at or near the site of the patient - enables doctors to make decisions on patients presenting with chest pain up to 20 minutes faster than those whose lab tests are evaluated by a standard lab.
  Abbott August 19, 2008  
• Corn farmers who use Monsanto advanced technology eligible for lower insurance premiums  Farmers in 11 states who plant a majority of their corn acres using hybrid seeds featuring YieldGard Plus with Roundup Ready Corn 2, YieldGard VT Triple and YieldGard VT Triple PRO technology from Monsanto Company will have an opportunity to lower their crop insurance premiums in 2009.
  Monsanto Company August 19, 2008  
• Snakes alive: Hiberna seeks help from nature to cure many diseases  Hiberna's Leslie Leinwand thinks that pythons and ground squirrels can benefit mankind. The Boulder-based startup is researching the metabolism of Burmese pythons and the hibernation of ground squirrels to develop drugs.
  Denver Business Journal August 15, 2008  Bob Mook
• OrthoLogic announces completion of dosing for second AZX100 Phase 1  OrthoLogic announced the completion of dosing for its second AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring. Patient follow-up is ongoing.
  OrthoLogic Corp. August 14, 2008  

   (next 10 articles)